Actively Recruiting
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
Led by European Foundation for Study of Chronic Liver Failure · Updated on 2025-08-06
189
Participants Needed
9
Research Sites
82 weeks
Total Duration
On this page
Sponsors
E
European Foundation for Study of Chronic Liver Failure
Lead Sponsor
U
Universität Münster
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the disease
CONDITIONS
Official Title
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Patients with decompensated cirrhosis admitted to hospital due to acute decompensation (AD) according to EASL-CLIF criteria
- Includes patients who developed acute-on-chronic liver failure (ACLF) during hospitalization
- Recovery from AD and expected discharge within the next 48 hours
You will not qualify if you...
- Admission for planned diagnostic or therapeutic procedures
- Active malignancy except hepatocellular carcinoma within Milan criteria or nonmelanocytic skin cancer
- Antiviral treatment for hepatitis C, B, or delta started in last 6 months or planned in next 6 months
- HIV positive unless under treatment and without clinical AIDS manifestations
- Ongoing alcohol use disorder with expected low prescription adherence
- Previous liver or other organ transplantation
- Presence of TIPS or other surgical porto-caval shunts
- Chronic organic renal failure stage IV or V or estimated GFR <20 ml/min
- Chronic heart failure NYHA class III or IV
- Pulmonary disease GOLD III or IV
- Significant extrahepatic disease with life expectancy under 6 months
- Severe psychiatric disorders
- Pregnancy or breastfeeding
- Expected low adherence to study protocol
- Unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Hospital Beaujon
Clichy, France, France, 92110
Actively Recruiting
2
University Hospital, Aachen
Aachen, Germany, Germany, 52074
Actively Recruiting
3
Universitätsklinikum Münster
Münster, Germany, Germany, 48149
Actively Recruiting
4
IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico di S.Orsola
Bologna, Italia, Italy, 40138
Actively Recruiting
5
A.O.U. Città della Salute e della Scienza di Torino
Torino, Italy, Italy, 10126
Actively Recruiting
6
Hospital Universitari Vall d'Hebron Research Institute
Barcelona, Spain, Spain, 08035
Actively Recruiting
7
Hospital Clinic de Barcelona
Barcelona, Spain, Spain, 08036
Actively Recruiting
8
Hospital Universitario Ramon y Cajal
Madrid, Spain, Spain, 28034
Actively Recruiting
9
Royal Free Hospital
London, United Kingdom, United Kingdom, NW3 2QG
Not Yet Recruiting
Research Team
A
Anna Bosch
CONTACT
C
Cristina Sánchez-Garrido
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here